Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death

Shih Chieh Chang1, Pooja Gopal1, Shuhui Lim1

  • 1Quantitative Biosciences, MSD, Singapore 119077, Singapore.

Cell Chemical Biology
|November 1, 2022
PubMed

Insights

Biodegraders offer a superior therapeutic approach by degrading target proteins like PCNA, unlike traditional inhibitors. This targeted protein degradation demonstrated potent anti-cancer effects and complete tumor inhibition in vivo.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biotechnology

Background:

  • Biodegraders are novel protein degradation constructs.
  • Proliferating cell nuclear antigen (PCNA) is a key oncology target.
  • Targeted protein degradation offers a potential therapeutic advantage over inhibition.

Purpose of the Study:

  • To investigate the efficacy of Con1-SPOP, a biodegrader targeting PCNA.
  • To compare the effects of biodegrader-mediated PCNA degradation with stoichiometric inhibition.
  • To evaluate the in vivo therapeutic potential of biodegraders.

Main Methods:

  • Utilized Con1-SPOP, a biodegrader targeting PCNA.
  • Compared Con1-SPOP with its stoichiometric inhibitor (Con1-SPOPmut).
  • Assessed anti-proliferative effects, DNA damage, apoptosis, and necrosis.
  • Employed proteomics to analyze downstream effects of PCNA degradation.
  • Evaluated in vivo tumor growth inhibition and mRNA delivery via lipid nanoparticles (LNPs).

Main Results:

  • Con1-SPOP exhibited superior anti-proliferative effects compared to Con1-SPOPmut.
  • PCNA degradation induced DNA damage, apoptosis, and necrosis.
  • Proteomics revealed impaired mitotic division and mitochondria dysfunction due to PCNA degradation.
  • Doxycycline-induced Con1-SPOP achieved complete tumor growth inhibition in vivo.
  • LNP-delivered mRNA encoding Con1-SPOP rapidly depleted endogenous PCNA with nanomolar potency.

Conclusions:

  • Biodegraders represent a powerful tool for biological research and therapy.
  • Targeted protein degradation is a more efficacious strategy than stoichiometric inhibition.
  • Biodegraders hold promise as a future therapeutic modality upon optimization of in vivo delivery.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K